Indivior PLC $INDV Shares Sold by Two Seas Capital LP

Two Seas Capital LP reduced its stake in shares of Indivior PLC (NASDAQ:INDV) by 51.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,109,198 shares of the company’s stock after selling 5,394,954 shares during the period. Indivior accounts for about 3.8% of Two Seas Capital LP’s holdings, making the stock its 3rd biggest position. Two Seas Capital LP owned about 4.09% of Indivior worth $183,318,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently modified their holdings of the stock. WINTON GROUP Ltd acquired a new position in shares of Indivior during the 4th quarter worth approximately $291,000. Vise Technologies Inc. acquired a new position in shares of Indivior during the 4th quarter worth approximately $256,000. Bank of New York Mellon Corp raised its position in shares of Indivior by 100.4% during the 4th quarter. Bank of New York Mellon Corp now owns 700,272 shares of the company’s stock worth $25,126,000 after purchasing an additional 350,839 shares during the last quarter. Natixis Advisors LLC acquired a new position in shares of Indivior during the 4th quarter worth approximately $376,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Indivior during the 4th quarter worth approximately $1,109,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

INDV has been the subject of several research reports. Weiss Ratings downgraded Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Indivior currently has a consensus rating of “Buy” and a consensus target price of $39.33.

Indivior Stock Performance

INDV stock opened at $37.62 on Friday. The stock has a market capitalization of $4.59 billion, a P/E ratio of 19.29 and a beta of 0.88. Indivior PLC has a one year low of $13.42 and a one year high of $41.00. The company has a 50 day moving average price of $34.61 and a two-hundred day moving average price of $34.10.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The company had revenue of $317.00 million during the quarter. Research analysts forecast that Indivior PLC will post 4.05 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.